. Author manuscript; available in PMC: 2013 Jul 1.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2011 Dec 2;83(3):887–894. doi: 10.1016/j.ijrobp.2011.07.041

Table 6.

Outcomes comparison to other studies

Study	No. of patients	Device/Method used	Toxicity	Radiologic Response	Survival times & rates
Rhee²³	42	Yttrium-90 (glass)	Grade III/IV (14%)	54%	Median:22 months
Rhee²³	42	Yttrium-90 (resin)	Grade III/IV (14%)	50%	Median: 28 months
Kennedy²	148	Yttrium-90	33% (grade III), fatigue (6.5%)	63%	Median: 70 months
King²⁵	58	Yttrium-90	Radiation gastritis (2 patients), duodenal ulcer (1 patient),	39%	Median : 36 months 1,2,3 year survival: 86%, 58%, and 47%
Saxena²⁴	48	Yttrium-90	0.5% (grade III) 1 patient (biliary obstruction)	54%	Median: 35 months 1,2,3 year survival: 87%, 62%, and 42%
Dong⁸	123	TACE	Abdominal pain (44%), diarrhea (30%), weight loss (22%)	62%	Mean: 3.3 years 3, 5 and 10 year survival : 59%, 36% and 20%
de Baere²⁶	20	TACE with doxorubicin eluting beads	Nausea (61%), fever (36%)	80%	-
Vogl²⁷	48	TACE with mitomycin C	Nausea and vomiting (27.8%), abdominal pain (11.1%)	11.1%	Median:38.6 7 months 5 year: 11.11%
Vogl²⁷	48	TACE with mitomycin C + gemcitabine	Nausea and vomiting (16.7%), abdominal pain (10%)	23.33%	Median: 57.1 5 year: 46.67%
Loewe²⁹	23	Bland embolization	-	73%	Median: 69 months 1 and 5 year survival: 95.7% and 65.4%
Eriksson³⁰	41	Bland Embolization	Postembolization syndrome (all), nausea (33%), fever (7 patients), median hospitalization: 12 days	50%	Median: 80 months 5 year: 60%
Current Study	40	Yttrium-90	Fatigue (63%, all grades), nausea/vomiting (40%, all grades), grade III, IV (bilirubin:8%; albumin:2%; lymphocute:38%)	WHO:64%; EASL: 63.9%	Median: 34.4 months 1,2, 3 year survival: 72.5%, 62.5%, 45%